BSEResult2d ago · 10 Nov 2026, 04:59 pm

Un-audited Financial Results for the Quarter and Half-year ended 30.09.2026.

Oxygenta Pharmaceutical Ltd · 524636

✦ AI SummaryResults

Oxygenta Pharmaceutical Ltd has announced its un-audited financial results for the quarter and half-year ended 30.09.2026. The Board of Directors has approved the results and a limited review report for the quarter ended 30.09.2026. The meeting was held on 10th November, 2026.

Analysis Scores

Earnings Impact5/10

Growth Catalyst2/10

Governance Concern1/10

Regulatory Risk1/10

Balance Sheet Risk3/10

Liquidity Impact8/10

Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

Full Announcement

Oxygenta Pharmaceutical Ltd - 524636 - Un-Audited Financial Results For The Quarter And Half-Year Ended 30.09.2026.

Attachments (1)

📄

d403c05e-fb42-4710-af0c-ddf850e14300.pdf

pdf

Download →

View document text

To Date: 10.11.2026 The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636) Sub: Outcome of Board Meeting With reference to the subject cited this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Tuesday, 10th November, 2026, at 12:30 p.m. at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter and half year ended 30.09.2026. (Attached) 2. Limited Review Report for the quarter ended 30.09.2026. (Attached) The Meeting concluded at 4:00 p.m. This is for the information and records of the Exchange, please. Thanking you. Yours faithfully, For Oxygenta Pharmaceutical Limited Balasubba Reddy Mamilla Whole-time Director (DIN: 01998852)